permit so that the permit expires either on the effective date of a final rule to establish a standard of identity for white chocolate, which may result from the petitions, or 30 days after termination of such rulemaking.

Hershey is now requesting that the extended temporary permit be amended to provide for up to 13,600,000 kg (30,000,000 lb) of a different product, containing white chocolate, that also contains chocolate cookies. Hershey is also requesting that the permit be amended to allow an additional plant where this product can be manufactured.

The agency finds that it is in the interest of the consumer to amend the extended temporary permit to allow for market testing of another product containing white chocolate. Therefore, under the provisions of § 130.17(f), FDA is modifying the extended temporary permit granted to Hershey to provide for the market testing of up to 13,600,000 kg (30,000,000 lb) of the new test product on an annual basis in addition to the 21,800,000 kg (48,000,000 lb) of test product authorized in the original permit. The new test product, in bar and bite size forms, will bear the fanciful name ''Hershey's Cookies 'n' Creme Chocolate Cookie Bits in White Chocolate.'' The white chocolate meets the compositional requirements of the current temporary permit. FDA is also modifying the extended temporary permit to provide for an additional plant at Hershey Chocolate, U.S.A., 19 East Chocolate Ave., Hershey, PA 17033, where the product may be manufactured. The product will be distributed nationwide.

Each of the ingredients used in the food must be declared on the label as required by the applicable sections of 21 CFR part 101. This amended extended permit expires either on the effective date of a final rule to establish a standard of identity for white chocolate, which may result from the petitions, or 30 days after termination of such rulemaking. All other conditions and terms of the extended permit remain the same.

Dated: December 15, 1995.

F. Edward Scarbrough,

Director, Office of Food Labeling, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–124 Filed 1–3–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95S–0199]

Report of the Fluoroquinolone Working Group; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the report of the Center for Veterinary Medicine's (CVM's) Fluoroquinolone Working Group (FQWG). The report addresses issues and contains recommendations regarding policies and procedures related to approval of fluoroquinolone (FQ) antimicrobial drugs in food animals. The report of the FQWG is in response to concerns that approval of FQ drugs for use in food animals may result in increased development of FQ resistance in zoonotic organisms harbored by food animals that are transmitted to humans and cause disease.

DATES: Written comments on the report may be submitted at any time.

ADDRESSES: Submit written requests for single copies of the report to the Communication and Education Branch (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send two self-addressed adhesive labels to assist that office in processing your requests. Submit written comments on the report to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville MD, 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. A copy of the report and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Linda A. Grassie, Center for Veterinary Medicine (HFV–12), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1755.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of the report of CVM's FQWG. The report addresses issues and recommendations concerning approval of FQ drugs for use in food animals. In response to concerns that approval of FQ drugs for use in food animals may result in increased development of FQ resistance in zoonotic organisms harbored by food animals that are transmitted to humans and cause disease. FDA convened a joint meeting of the CVM and Center for Drug Evaluation and Research advisory committees on May 11 and 12, 1994. Members of the joint advisory committee stated that FQ drugs could be approved for use in food animals, if CVM restricts their use so that FQ's are safe and effective under approved conditions of use and recommended that CVM monitor the emergence of FQ resistance. In response to the public health concerns that were raised, CVM formed the FQWG to provide recommendations of policies and procedures relevant to the approval of FQ drugs in food animals. FDA is announcing that the report of the FQWG has been accepted by the Director, CVM, and is available for public inspection and comment.

Interested persons may, at any time, submit to the Dockets Management Branch (address above) written comments on the report of CVM's FQWG. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in the heading of this document. The report, appendices, and comments may be seen at the Dockets Management Branch (address above), between 9 a.m. and 4 p.m., Monday through Friday.

The report and recommendations represent the agency's current position on the issues discussed therein, however, they do not create or confer any rights, privileges, or benefits for or on any person, nor do they operate to bind FDA in any way. CVM will consider any comments received in determining the continued appropriateness of the recommendations in the report regarding the approval of FQ's for animal use.

Dated: December 27, 1995.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–125 Filed 1–3–96; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Secretary

[Docket No. FR–4007–D–01]

Delegation of Concurrent Authority to the Deputy Secretary

AGENCY: Office of The Secretary, HUD.

ACTION: Notice of delegation of concurrent authority.